Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicityCharlotte Graham, Kathleen Gallagher, Won‐Ho Lee et al.|Blood|2023Cited by 65
Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma PatientsIna Ly, Elizabeth R. Gerstner, Leland G. Richardson et al.|Clinical Cancer Research|2023Cited by 22
ATIM-37. PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RADIATION (HFRT) FOR ADULT PATIENTS WITH SECONDARILY TRANSFORMED IDH-MUTANT GLIOBLASTOMA (GBM)Sylvia C. Kurz, Joshua S. Silverman, Tsivia Hochman et al.|Neuro-Oncology|2019Cited by 3
Correction: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic PathwaysSriram Venneti, Debra Hawes, Abed Rahman Kawakibi et al.|Cancer Discovery|2025Cited by 2
ATIM-01. A PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RE-IRRADIATION IN ADULT SUBJECTS WITH TRANSFORMED IDH MUTANT GLIOBLASTOMAJoshua S. Silverman, Sylvia Eisele, Isabel Arrillaga‐Romany et al.|Neuro-Oncology|2017Cited by 0